The restoration of kidney mitochondria function by inhibition of angiotensin-II production in rats with acute adriamycin-induced nephrotoxicity

References

• Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol. 2007;23(1):15–25
   PubMed Web of Science ®Google Scholar
• Malarkodi KP, Balachandar AV, Varalakshmi P. Protective effect of lipoic acid on Adriamycin induced lipid peroxidation in rat kidney. Mol Cell Biochem. 2003;247(1–2):9–13
   PubMedGoogle Scholar
• Malarkodi KP, Balachandar AV, Varlakshmi P. The influence of lipoic acid on Adriamycin-induced hyperlipidemic nephrotoxicity in rats. Mol Cell Biochem. 2003;247(1–2):139–145
   PubMedGoogle Scholar
• Ajith TA, Aswathy MS, Hema U. Protective effect of Zingiber officinale roscoe against anticancer drug doxorubicin-induced acute nephrotoxicity. Food Chem Toxicol. 2008;46(9):3178–3181
   PubMed Web of Science ®Google Scholar
• Dursun N, Taskin E, Ozturk F. Protection against Adriamycin-induced cardiomyopathy by carnosine in rats: role of endogenous antioxidants. Biol Trace Elem Res. 2011;143(1):412–424
   PubMedGoogle Scholar
• Dursun N, Taskin E, Yerer Aycan MB, Sahin L. Selenium-mediated cardioprotection against Adriamycin-induced mitochondrial damage. Drug Chem Toxicol. 2011;34(2):199–207
   PubMed Web of Science ®Google Scholar
• Hou XW, Jiang Y, Wang LF, et al. Protective role of granulocyte colony-stimulating factor against Adriamycin induced cardiac, renal and hepatic toxicities. Toxicol Lett. 2009;187(1):40–44
   PubMedGoogle Scholar
• Ozdogan K, Taskin E, Dursun N. Protective effect of carnosine on Adriamycin-induced oxidative heart damage in rats. AKD Anatolian J Cardiol. 2011;11(1):3–10
   Google Scholar
• Taskin E, Dursun N. The protection of selenium on Adriamycin-induced mitochondrial damage in rat. Biol Trace Elem Res. 2012;147(1–3):165–171
   PubMed Web of Science ®Google Scholar
• Harake D, Franco VI, Henkel JM, Miller TL, Lipshultz SE. Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. Future Cardiol. 2012;8(4):647–670
   PubMedGoogle Scholar
• Konorev EA, Kennedy MC, Kalyanaraman B. Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates. Arch Biochem Biophys. 1999;368(2):421–428
   PubMedGoogle Scholar
• Chandran K, Aggarwal D, Migrino RQ, et al. Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q. Biophys J. 2009;96(4):1388–1398
   PubMed Web of Science ®Google Scholar
• Wallace KB, Starkov AA. Mitochondrial targets of drug toxicity. Annu Rev Pharmacol Toxicol. 2000;40:353–388
   PubMed Web of Science ®Google Scholar
• Morin D, Barthelemy S, Zini R, Labidalle S, Tillement JP. Curcumin induces the mitochondrial permeability transition pore mediated by membrane protein thiol oxidation. FEBS Lett. 2001;495(1–2):131–136
   PubMedGoogle Scholar
• Mimnaugh EG, Trush MA, Bhatnagar M, Gram TE. Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug Adriamycin. Biochem Pharmacol. 1985;34(6):847–856
   PubMedGoogle Scholar
• Ji LL, Mitchell EW. Effects of Adriamycin on heart mitochondrial function in rested and exercised rats. Biochem Pharmacol. 1994;47(5):877–885
   PubMedGoogle Scholar
• Ji Z, Huang C, Liang C, Chen B, Chen S, Sun W. Protective effects of blocking renin-angiotensin system on the progression of renal injury in glomerulosclerosis. Cell Mol Immunol. 2005;2(2):150–154
   PubMedGoogle Scholar
• Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res. 2009;60(5):373–381
   PubMed Web of Science ®Google Scholar
• Rashikh A, Pillai KK, Ahmad SJ, Akhtar M, Najmi AK. Aliskiren alleviates doxorubicin-induced nephrotoxicity by inhibiting oxidative stress and podocyte injury. J Renin Angiotensin Aldosterone Syst. 2013;14(1):14–22
   PubMed Web of Science ®Google Scholar
• Han P, Sun H, Xu Y, et al. Lisinopril protects against the adriamycin nephropathy and reverses the renalase reduction: potential role of renalase in adriamycin nephropathy. Kidney Blood Press Res. 2013;37(4–5):295–304
   PubMedGoogle Scholar
• Arozal W, Watanabe K, Veeraveedu PT, et al. Effect of telmisartan in limiting the cardiotoxic effect of daunorubicin in rats. J Pharm Pharmacol. 2010;62(12):1776–1783
   PubMedGoogle Scholar
• Nakamae H, Tsumura K, Terada Y, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005;104(11):2492–2498
   PubMed Web of Science ®Google Scholar
• Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013;65(2):157–170
   PubMed Web of Science ®Google Scholar
• de Cavanagh EM, Inserra F, Ferder M, Ferder L. From mitochondria to disease: role of the renin-angiotensin system. Am J Nephrol. 2007;27(6):545–553
   PubMedGoogle Scholar
• Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52(6):1213–1225
   PubMed Web of Science ®Google Scholar
• Okasora T, Takikawa T, Utsunomiya Y, et al. Suppressive effect of superoxide dismutase on Adriamycin nephropathy. Nephron. 1992;60(2):199–203
   PubMedGoogle Scholar
• Bertani T, Cutillo F, Zoja C, Broggini M, Remuzzi G. Tubulo-interstitial lesions mediate renal damage in Adriamycin glomerulopathy. Kidney Int. 1986;30(4):488–496
   PubMed Web of Science ®Google Scholar
• Mimnaugh EG, Trush MA, Gram TE. A possible role for membrane lipid peroxidation in anthracycline nephrotoxicity. Biochem Pharmacol. 1986;35(23):4327–4335
   PubMedGoogle Scholar
• Mansour MA, El-Kashef HA, Al-Shabanah OA. Effect of captopril on doxorubicin-induced nephrotoxicity in normal rats. Pharmacol Res. 1999;39(3):233–237
   PubMedGoogle Scholar
• Rashikh A, Abul Kalam N, Akhtar M, Mahmood D, Pillai KK, Ahmad SJ. Protective effects of aliskiren in doxorubicin-induced acute cardiomyopathy in rats. Human Exp Toxicol. 2011;30(2):102–109
   PubMedGoogle Scholar
• Boucek RJ Jr, Steele A, Miracle A, Atkinson J. Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol. 2003;3(4):319–329
   PubMedGoogle Scholar
• Giri SN, Al-Bayati MA, Du X, Schelegle E, Mohr FC, Margolin SB. Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats. Cancer Chemother Pharmacol. 2004;53(2):141–150
   PubMedGoogle Scholar
• Yamanaka N, Kato T, Nishida K, Fujikawa T, Fukushima M, Ota K. Elevation of serum lipid peroxide level associated with doxorubicin toxicity and its amelioration by [dl]-alpha-tocopheryl acetate or coenzyme Q10 in mouse (doxorubicin, toxicity, lipid peroxide, tocopherol, coenzyme Q10). Cancer Chemother Pharmacol. 1979;3(4):223–227
   PubMedGoogle Scholar
• Wang YM, Madanat FF, Kimball JC, et al. Effect of vitamin E against Adriamycin-induced toxicity in rabbits. Cancer Res. 1980;40(4):1022–1027
   PubMedGoogle Scholar
• Pandir D, Kara O. Cisplatin-induced kidney damage and the protective effect of bilberry (Vaccinium myrtillus L.): an experimental study. Turkish J Med Sci. 2013;43(6):951–956
   Google Scholar
• Munoz M, Rincon J, Pedreanez A, Viera N, Hernandez-Fonseca JP, Mosquera J. Proinflammatory role of angiotensin II in a rat nephrosis model induced by Adriamycin. J Renin Angiotensin Aldosterone Syst. 2011;12(4):404–412
   PubMedGoogle Scholar
• Ulu N, Buikema H, van Gilst WH, Navis G. Vascular dysfunction in Adriamycin nephrosis: different effects of Adriamycin exposure and nephrosis. Nephrol Dial Transplant. 2008;23(6):1854–1860
   PubMedGoogle Scholar
• Hiona A, Lee AS, Nagendran J, et al. Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function. J Thorac Cardiovasc Surg. 2011;142(2):396–403 e393
   PubMedGoogle Scholar
• Dagenais NJ, Jamali F. Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. Pharmacotherapy. 2005;25(9):1213–1229
   PubMed Web of Science ®Google Scholar
• Westermann D, Riad A, Lettau O, et al. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension. 2008;52(6):1068–1075
   PubMed Web of Science ®Google Scholar
• Rashikh A, Pillai KK, Najmi AK. Protective effect of a direct renin inhibitor in acute murine model of cardiotoxcity and nephrotoxicity. Fundam Clin Pharmacol. 2013. [Epub ahead of print]. doi: 10.1111/fcp.12054
   Google Scholar
• St-Jacques R, Toulmond S, Auger A, et al. Characterization of a stable, hypertensive rat model suitable for the consecutive evaluation of human renin inhibitors. JRAAS. 2011;12(3):133–145
   Google Scholar
• Muller DN, Derer W, Dechend R. Aliskiren – mode of action and preclinical data. J Mol Med (Berl). 2008;86(6):659–662
   PubMedGoogle Scholar